Joan Albanell

19.5k total citations · 5 hit papers
251 papers, 12.6k citations indexed

About

Joan Albanell is a scholar working on Oncology, Molecular Biology and Cancer Research. According to data from OpenAlex, Joan Albanell has authored 251 papers receiving a total of 12.6k indexed citations (citations by other indexed papers that have themselves been cited), including 179 papers in Oncology, 76 papers in Molecular Biology and 76 papers in Cancer Research. Recurrent topics in Joan Albanell's work include HER2/EGFR in Cancer Research (79 papers), Monoclonal and Polyclonal Antibodies Research (36 papers) and Cancer Treatment and Pharmacology (33 papers). Joan Albanell is often cited by papers focused on HER2/EGFR in Cancer Research (79 papers), Monoclonal and Polyclonal Antibodies Research (36 papers) and Cancer Treatment and Pharmacology (33 papers). Joan Albanell collaborates with scholars based in Spain, United States and United Kingdom. Joan Albanell's co-authors include José Baselga, Federico Rojo, Ana Rovira, Joaquı́n Arribas, John Mendelsohn, Youngmee Kim, Jordi Codony‐Servat, Aňa Lluch, José Baselga and Larry Norton and has published in prestigious journals such as Nature Medicine, Nature Communications and Journal of Clinical Oncology.

In The Last Decade

Joan Albanell

245 papers receiving 12.3k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts.

1998 811 citations José Baselga, Joan Albanell et al. PubMed profile →
Phase I Safety, Pharmacokinetic, and Pharmacodynamic Trial of ZD1839, a Selective Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Five Selected Solid Tumor Types

2002 683 citations José Baselga, Federico Rojo et al. profile →
Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells.

2001 614 citations Jordi Codony‐Servat, Joan Albanell et al. PubMed profile →
A SNAIL1–SMAD3/4 transcriptional repressor complex promotes TGF-β mediated epithelial–mesenchymal transition

2009 535 citations Federico Rojo, Joan Albanell et al. profile →
Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer

2012 367 citations Marta Salido, Joaquim Bellmunt et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Joan Albanell Spain	56	7.9k	4.8k	3.0k	2.9k	2.4k	251	12.6k
Federico Rojo Spain	52	7.6k 1.0×	7.1k 1.5×	2.6k 0.9×	3.3k 1.1×	1.9k 0.8×	267	13.5k
P. Fumoleau France	61	9.6k 1.2×	3.3k 0.7×	4.4k 1.5×	2.7k 0.9×	2.3k 0.9×	326	14.3k
Young‐Hyuck Im South Korea	51	8.7k 1.1×	2.9k 0.6×	3.8k 1.3×	3.7k 1.3×	2.5k 1.0×	270	12.4k
Luc Dirix Belgium	65	9.4k 1.2×	4.4k 0.9×	4.6k 1.5×	3.4k 1.2×	1.4k 0.6×	311	14.6k
Ingrid A. Mayer United States	46	6.0k 0.8×	5.0k 1.0×	3.4k 1.1×	3.3k 1.1×	1.8k 0.7×	210	12.0k
Ronald Simon Germany	63	5.2k 0.7×	6.9k 1.4×	3.4k 1.2×	3.9k 1.3×	1.2k 0.5×	357	13.5k
Francisco J. Esteva United States	68	11.6k 1.5×	7.0k 1.5×	4.6k 1.6×	3.2k 1.1×	4.9k 2.0×	280	18.0k
George Somlo United States	51	6.1k 0.8×	4.7k 1.0×	3.8k 1.3×	1.8k 0.6×	957 0.4×	279	12.2k
Robert L. Camp United States	56	5.7k 0.7×	6.2k 1.3×	2.4k 0.8×	2.3k 0.8×	1.2k 0.5×	118	12.8k
Aňa Lluch Spain	55	10.3k 1.3×	4.1k 0.9×	6.1k 2.1×	2.5k 0.8×	2.7k 1.1×	306	14.7k

Countries citing papers authored by Joan Albanell

Since Specialization

Citations

This map shows the geographic impact of Joan Albanell's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Joan Albanell with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Joan Albanell more than expected).

Fields of papers citing papers by Joan Albanell

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Joan Albanell. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Joan Albanell. The network helps show where Joan Albanell may publish in the future.

Co-authorship network of co-authors of Joan Albanell

This figure shows the co-authorship network connecting the top 25 collaborators of Joan Albanell. A scholar is included among the top collaborators of Joan Albanell based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Joan Albanell. Joan Albanell is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Lameirinhas, Ana, Iris Garrido‐Cano, Cristina Hernándo, et al.. (2025). Involvement of microRNAs-449/FASN axis in response to trastuzumab therapy in HER2-positive breast cancer. Molecular Medicine. 31(1). 116–116.

Casadevall, David, Sara García‐Alonso, Sílvia Menéndez, et al.. (2022). mTOR Inhibition and T-DM1 in HER2-Positive Breast Cancer. Molecular Cancer Research. 20(7). 1108–1121. 15 indexed citations

Rivas, Elisa, Jenniffer Linares, Melissa Zwick, et al.. (2022). Targeted immunotherapy against distinct cancer-associated fibroblasts overcomes treatment resistance in refractory HER2+ breast tumors. Nature Communications. 13(1). 5310–5310. 40 indexed citations

Muntasell, Aura, Federico Rojo, Sònia Servitja, et al.. (2019). NK Cell Infiltrates and HLA Class I Expression in Primary HER2+ Breast Cancer Predict and Uncouple Pathological Response and Disease-free Survival. Clinical Cancer Research. 25(5). 1535–1545. 89 indexed citations

Rodríguez‐Vida, Alejo, Núria Juanpere, Oriol Arpí, et al.. (2019). Novel Oral mTORC1/2 Inhibitor TAK-228 Has Synergistic Antitumor Effects When Combined with Paclitaxel or PI3Kα Inhibitor TAK-117 in Preclinical Bladder Cancer Models. Molecular Cancer Research. 17(9). 1931–1944. 27 indexed citations

Tormo, Eduardo, Anna Adam‐Artigues, Sandra Ballester, et al.. (2017). The role of miR-26a and miR-30b in HER2+ breast cancer trastuzumab resistance and regulation of the CCNE2 gene. Scientific Reports. 7(1). 41309–41309. 61 indexed citations

Rincón, Raúl, Sandra Zazo, Cristina Chamizo, et al.. (2016). c-Jun N-Terminal Kinase Inactivation by Mitogen-Activated Protein Kinase Phosphatase 1 Determines Resistance to Taxanes and Anthracyclines in Breast Cancer. Molecular Cancer Therapeutics. 15(11). 2780–2790. 12 indexed citations

Alba, Emilio, Joan Albanell, Juan de la Haba-Rodríguez, et al.. (2014). Trastuzumab or lapatinib with standard chemotherapy for HER2-positive breast cancer: results from the GEICAM/2006-14 trial. British Journal of Cancer. 110(5). 1139–1147. 55 indexed citations

Martín-Martorell, Paloma, B. Bermejo De Las Heras, José Alejandro Pérez Fidalgo, et al.. (2014). Subcutaneous trastuzumab: drug development and current position. Clinical & Translational Oncology. 16(10). 859–864. 2 indexed citations

10.

Stanisavljević, Jelena, Jordina Loubat‐Casanovas, Mercedes Herrera, et al.. (2014). Snail1-Expressing Fibroblasts in the Tumor Microenvironment Display Mechanical Properties That Support Metastasis. Cancer Research. 75(2). 284–295. 98 indexed citations

11.

Cañadas, Israel, Federico Rojo, Álvaro Taus, et al.. (2013). Targeting Epithelial-to-Mesenchymal Transition with Met Inhibitors Reverts Chemoresistance in Small Cell Lung Cancer. Clinical Cancer Research. 20(4). 938–950. 107 indexed citations

12.

Rojo, Federico, Laia Domingo, María Sala, et al.. (2013). Gene Expression Profiling in True Interval Breast Cancer Reveals Overactivation of the mTOR Signaling Pathway. Cancer Epidemiology Biomarkers & Prevention. 23(2). 288–299. 10 indexed citations

13.

Martinez‐García, Maria, Udai Banerji, Joan Albanell, et al.. (2012). First-in-Human, Phase I Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of RO5126766, a First-in-Class Dual MEK/RAF Inhibitor in Patients with Solid Tumors. Clinical Cancer Research. 18(17). 4806–4819. 122 indexed citations

14.

Sánchez‐Rovira, Pedro, Marta Salido, José L. García-Puche, et al.. (2012). Biomarkers characterization of circulating tumour cells in breast cancer patients. Breast Cancer Research. 14(3). R71–R71. 79 indexed citations

15.

Sáez, Rosana, Miguel Ángel Molina‐Vila, Elizabeth E. Ramsey, et al.. (2006). p95HER-2 Predicts Worse Outcome in Patients with HER-2-Positive Breast Cancer. Clinical Cancer Research. 12(2). 424–431. 161 indexed citations

16.

Codony‐Servat, Jordi, Marta Bosch, Cristina Oliva, et al.. (2006). Differential cellular and molecular effects of bortezomib, a proteasome inhibitor, in human breast cancer cells. Molecular Cancer Therapeutics. 5(3). 665–675. 88 indexed citations

17.

Codony‐Servat, Jordi, et al.. (2001). Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells.. PubMed. 61(12). 4744–9. 614 indexed citations breakdown →

18.

Albanell, Joan & José Baselga. (1999). The ErbB Receptors as Targets for Breast Cancer Therapy. Journal of Mammary Gland Biology and Neoplasia. 4(4). 337–351. 24 indexed citations

19.

Codony‐Servat, Jordi, Joan Albanell, Juan Carlos López-Talavera, Joaquı́n Arribas, & José Baselga. (1999). Cleavage of the HER2 ectodomain is a pervanadate-activable process that is inhibited by the tissue inhibitor of metalloproteases-1 in breast cancer cells.. PubMed. 59(6). 1196–201. 193 indexed citations

20.

Mendelsohn, John, et al.. (1997). PD153035, a tyrosine kinase inhibitor, prevents epidermal growth factor receptor activation and inhibits growth of cancer cells in a receptor number-dependent manner.. PubMed. 3(11). 2099–106. 176 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact